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Introduction
Lung resection is indicated for several conditions, including 
curative resection for lung cancer and limited resection for 
diagnostic purposes. It has become less invasive owing to 
advancement in surgical procedures. However, patients with 
respiratory comorbidities are susceptible to loss of function 
after surgery and a high proportion of postoperative 
complications. Therefore, risk assessment and perioperative 
management are essential, depending on the disease.
Some studies in patients with interstitial pneumonia have 
reported the efficacy of perioperative pirfenidone. They 
also reported that sialylated carbohydrate antigen (KL-6) 
levels and the diffusing capacity of carbon monoxide are 
poor prognostic factors (1-3). However, few conventional 
indicators are available for chronic obstructive pulmonary 
disease (COPD), which has a higher prevalence, and further 
universal risk factors should be investigated.
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The novel concept of asthma-COPD overlap has been 
proposed recently, which presents with a combination of 
the features of chronic lung disease. Airway inflammation 
has been studied with respect to its contribution to disease 
progression (4). Airway inflammation is quantified using 
fractional exhaled nitric oxide (FeNO), which is widely used 
in daily practice, because it can be easily measured (4), but 
its impact on lung resection remains unknown.
We hypothesized that a state of high airway inflammation 
is associated with adverse effects on the clinical course. 
The purpose of this prospective study was to identify the 
potential risk in patients using FeNO and examine the 
clinical significance of airway inflammation measurement in 
patients who underwent lung resection.
Methods
Patients and study design
This single-center, prospective study was conducted at 
Shiga University of Medical Science Hospital and was 
approved by the appropriate institutional review boards 
(protocol number 29-175). Written informed consent was 
obtained from each participant.
This study included adult patients younger than 
90 years of age, who underwent elective lung resection 
at the Department of General Thoracic Surgery, Shiga 
Medical University of Medical Science (Shiga, Japan) 
between September 2017 and March 2019. We measured 
FeNO in participants who provided informed consent, 
in addition to routine preoperative blood, physiological 
function, and imaging tests. The exclusion criteria were as 
follows: patients aged under 20 years, those with a history 
of treatment for infection within the past 1 month, those 
suspected of active pulmonary infection on admission, those 
using immunosuppressants, and patients in whom FeNO 
examination could not be performed satisfactorily.
Study setting
The participants’ airway inflammation and subjective 
symptoms were evaluated once before and on days 1, 3, 5–7 
after surgery, for a total of 4 times. Airway inflammation 
was measured as FeNO using NIOX VERO® (NOV, 
Aerocrine, Solna, Sweden). Measurements were made 
during the day, except for 2 hours after meals and after 
waking up. We simultaneously interviewed patients 
regarding their symptoms, which were recorded with the 
COPD assessment test (CAT) (5) using only 3 items (cough, 
sputum, dyspnea) from the CAT questionnaire, considering 
the patients’ inconvenience after surgery. The total score of 
the modified CAT was 21.
The primary endpoint was the relationship between 
postoperative morbidity in the hospital and preoperative 
FeNO. The Clavien-Dindo and postoperative pulmonary 
complications (PPCs) classifications were used to evaluate 
morbidity (6,7). Major complications were defined as grade 
3 or higher on the Clavien-Dindo classification. One of 
the secondary endpoints was to clarify the perioperative 
dynamics of airway inflammation. Postoperative FeNO 
levels were described with respect, to preoperative levels, 
and the difference was analyzed. Another secondary 
endpoint included the investigation of the relationship 
between increased airway inflammation and respiratory 
events comprising additional medical treatment within 
30 days and readmission within 90 days of surgery.
We also prospectively recorded the following variables: 
sex, age, body mass index, smoking history (Brinkman 
index), medical history [Charlson Comorbidity index (CCI) 
score] (8), tumor diameter measured using computed 
tomography, blood test findings (carcinoembryonic antigen, 
KL-6, brain natriuretic peptide, and hemoglobin A1c), 
respiratory function [vital capacity (VC), forced expiratory 
volume in 1 second (FEV1.0) and their predicted values 
(%VC, %FEV1.0)], surgery-related findings (procedure, 
approach, duration time, and blood loss), and pathological 
findings of lung tumor.
Statistical analysis
Statistical analysis was performed using SPSS software, 
version 22.0 (IBM, Inc., CA, USA). All continuous 
values were expressed as mean ± standard deviation (SD). 
The peak value of postoperative FeNO was used as the 
representative value, when it was used as a variable during 
statistical analysis. A multivariate logistic regression 
model was used to analyze the predictors of postoperative 
complications and additional respiratory-event related 
treatment. Baseline variables with P values <0.250 obtained 
from univariate analysis were included in the multivariable 
models. The chi-squared test was used for comparing 
categorical variable. The t-test and Mann-Whitney’s U test 
were used for comparing continuous variables. Pearson’s 
correlation coefficient and linear regression analysis were 
used to determine the relationship between postoperative 
FeNO levels and the modified CAT score. P values <0.05 
were considered to be statistically significant.
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Results
Figure 1 summarizes the patients who participated in 
this study (n=105). The characteristics of all patients are 
presented in Table 1. Men were predominant in the study 
population. The proportion of primary lung cancer was the 
highest. The percentage of the anatomical lung resection 
approach was 87%. None of the patients required extended 
surgery owing to intraoperative findings. Lobectomy 
was performed as radical surgery for lung cancer, and 
segmentectomy and wedge resection were adopted as 
conservative approaches for diagnosis or treatment.
Major complications developed in 8 patients (8%), 
which included chylothorax (n=2), pulmonary fistula (n=2), 
hypoxia (n=3), and bronchospasm (n=1). PPCs developed 
in 16 patients (15%). PPCs consisted of pneumonitis and 
bronchiolitis (n=6), bronchospasm (n=3), hypoxia (n=3), 
pulmonary fistula (n=2), and atelectasis (n=2). Additional 
medical treatment within 30 days of surgery comprised 
cough medication alone (n=26), antibacterial agents (n=8), 
antiviral drugs (n=1), intravenous corticosteroids (n=3), 
and inhalational corticosteroids (n=3). Two patients were 
readmitted within 90 days of surgery, owing to bacterial 
pneumonia and acute exacerbation of interstitial pneumonia, 
respectively. The 90-day mortality was 0. The following 
predictors of postoperative morbidity were identified 
among all patients, based on statistical analysis (Table 2). 
Multivariate analysis revealed that operating time was a 
significant predictor of major complications [P=0.004, odds 
ratio (OR): 1.012, 95% confidence interval (CI): 1.004–
1.021] and preoperative FeNO was a significant predictor of 
PPCs (P=0.002, OR: 1.004, 95% CI: 1.016–1.074) (Table 2).
The distribution of perioperative FeNO levels is shown 
in Figure 2. The mean FeNO level increased significantly 
after surgery (P=0.011) in all patients, but no significant 
difference was observed after dividing it by surgical 
procedure. Figure 3 shows the changes in postoperative 
FeNO levels and modified CAT scores. FeNO levels 
peaked on the first day postoperatively in the anatomic lung 
resection group and on the third day postoperatively in 
the wedge resection group. The results of the correlation 
analysis between postoperative FeNO and modified CAT 
scores were P=0.250, r=0.250, P=0.625, r=−0.556 and 
P=0.819, r=0.280 in the lobectomy, segmentectomy and 
wedge resection groups, respectively.
Statistical analysis was performed to determine the 
relationship between the secondary endpoints and variables, 
including postoperative FeNO (Table 3). Multivariate 
analysis revealed that postoperative FeNO was a significant 
predictor of additional medical treatment within 30 days of 
surgery (P=0.001, OR: 1.068, 95% CI: 1.028–1.110). No 
predictors for readmission were discovered on univariate 
and multivariate analyses.
Discussion
The principal f inding of this study was that high 
preoperative FeNO affected the development of PPCs after 
lung resection surgery. We also demonstrated postoperative 
FeNO dynamics and that patients with elevated levels were 
Figure 1 Overview of the study population. FeNO, fractional exhaled nitric oxide.
Informed consent for study participation
Patients who measured preoperative 
FeNO and underwent lung resection
(n=105, Table 1)
Analysis of primary endpoint
• postoperative complications, Table 2
Analysis of secondary endpoints
• dynamics of postoperative FeNO, Figures 2,3
• additional medical treatment, Table 3
Patients who could not measure postoperative
due to occurrence of complications
• intubation with airway spasm (n=1)
• pneumonia, respiratory failure (n=2)
• cerebrospinal fluid leakage with epidural puncture (n=1)
due to lack of understanding of measurement technique (n=1)
due to patient’s refusal to measure (n=1)
Patients who measured postoperative 
FeNO the specified number of times
(n=99)
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Table 1  The demographics of the patients enrolled in this study
Variables n=105
Male, n [%] 61 [58]
Age (years) 68.5±10.2
BMI (kg/m2) 22.6±3.2
Smoking, Brinkman index 510±579
Performance status 1, n [%] 4 [4]
CCI score 1.2±1.5
Tumor diameter (mm) 21.7±11.5
CEA (ng/mL) 4.4±3.2
KL-6 (U/mL) 296±159
Preoperative FeNO (ppm) 26.7±17.5
BNP (pg/mL) 29.3±37.7






Operative time (min) 246±101






Open thoracotomy 14 [13]
VATS 91 [87]
Pathology, n [%]
Lung cancer 90 [86]
Other malignancies 8 [8]
Benign 7 [6]
Major complications, n [%] 8 [8]
Postoperative pulmonary complications, n 
[%]
16 [15]
Additional medical treatment, n [%] 43 [41]
Respiratory related readmission, n [%] 2 [2]
Mortality, n [%] 0 (0)
BMI, body mass index; CCI, Charlson Comorbidity index; 
CEA, carcinoembryonic antigen; KL-6, sialylated carbohydrate 
antigen; BNP, brain natriuretic peptide; FeNO, fractional exhaled 
nitric oxide; VC, vital capacity; FEV1.0, forced expiratory volume 
in 1 s; VATS, video-assisted thoracic surgery.
more likely to require additional medical treatment.
FeNO, which is significantly correlated with sputum 
eosinophils (9), can reflect Th2-driven airway inflammation, 
which results in the upregulation of inducible nitric oxide 
synthase in the bronchial epithelium (10,11). FeNO is 
regarded as an indicator of respiratory disease with high 
bronchial inflammation, including asthma and ACO (12). It 
is widely used since it can be measured easily (13). Clinical 
research using conventional methods is generally avoided 
because forced cough and spirometry in the postoperative 
acute phase can lead to worsening of the patient’s 
condition. However, our evaluation method overcame these 
disadvantages and may be used in clinical settings.
We studied multiple surgical procedures and found that 
prolonged procedures such as lobectomy for lung cancer may 
have been responsible for major complications (Table 2). The 
Clavien-Dindo classification covers a wide range of surgical 
complications. However, it cannot adequately represent 
respiratory status in detail (14-16). We used PPCs in order to 
clearly define these individual adverse effects, which helped to 
prove our hypothesis. PPCs are especially associated with early 
postoperative mortality (17), and measurement of preoperative 
FeNO was valuable in preventing respiratory complications 
and subsequent deterioration.
We analyzed perioperative FeNO dynamics but failed 
to observe any statistical difference between each surgical 
procedure. Initially, we thought that the postoperative 
increase in FeNO values would be prominent for generally 
invasive procedures, including lobectomy. However, the 
increase was most pronounced (P=0.068) in the wedge-
resection group, and unlike the other groups, it peaked on 
the third day, postoperatively. Complications and steroid 
therapy after surgery may have been responsible for false-
negative airway inflammation levels in some patients. We 
assumed that neutrophilic inflammation caused by bronchial 
incision progressed soon after surgery and eosinophilic 
inflammation was suppressed in the anatomical resection 
group. Pain caused by surgical factors such as wound size 
and approach was thought to have contributed to the results 
of the symptom scores.
The results presented in Table 3 suggest that the local 
exacerbation of eosinophilic inflammation after surgery 
increased the need for additional treatment. Aggressive anti-
inflammatory treatment, including early steroid inhalation 
therapy, may regulate the environment of the lower airway 
and improve the patient’s condition quickly. Further 
investigations with a larger sample size are required, to 
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Table 2 Variables and analysis data of the predictors according to complications
Variables











Male, n 5 56 0.550 – 9 52 0.871 –
Age (years) 71.5±5.2 68.2±10.4 0.396 – 71.6±11.0 67.9±9.9 0.182 0.162
BMI ≥25 (kg/m2), n 2 23 0.611 – 7 18 0.048 0.100
Smoking, Brinkman index 711±866 493±555 0.506 – 485±678 515±567 0.850 –
Performance status 1, n 1 3 0.184 0.438 2 2 0.345 –
CCI score 1.1±1.4 1.6±1.4 0.315 – 1.1±1.4 1.4±1.4 0.050 0.305
Tumor diameter (mm) 18.3±9.6 17.0±13.3 0.790 – 18.9±8.8 16.8±13.7 0.563 –
CEA (ng/mL) 5.1±2.2 4.3±3.2 0.475 – 5.7±2.2 4.1±3.3 0.020 0.128
KL-6 (U/mL) 357±259 285±149 0.466 – 338±231 282±143 0.362 –
Preoperative FeNO (ppb) 38.7±29.4 25.7±16.0 0.256 – 41.3±29.5 24.1±13.0 0.036 0.002
BNP (pg/mL) 57.0±106 27.0±25.7 0.450 – 44.6±77.5 26.5±24.8 0.369 –
Hemoglobin A1c, (%) 6.0±0.5 5.8±0.5 0.316 – 5.8±0.5 5.8±0.5 0.953 –
VC (mL) 3,111±630 3,346±809 0.425 – 3,110±657 3,368±817 0.235 0.271
%VC (%) 99.9±7.2 103±14.0 0.497 – 100±10.9 103±14.1 0.383 –
FEV1.0 (mL) 2,040±544 2,453±647 0.083 0.064 2,136±585 2,473±647 0.055 0.080
%FEV1.0 (%) 85.7±13.0 97.7±16.5 0.048 0.106 89.1±17.6 98.2±16.1 0.043 0.062
Operative time (min) 361±131 234±93 0.001 0.005 281±136 237±93 0.116 0.240
Operative blood loss (mL) 181±136 55.9±84.4 0.035 0.347 119±116 55.8±87.5 0.051 0.158
Lobectomy, n 6 65 0.488 – 10 61 0.635 –
Anatomical lung resection, n 8 78 0.190 0.678 13 73 0.589 –
Open thoracotomy, n 2 12 0.289 – 3 11 0.361 –
Lung cancer, n 7 83 0.680 – 14 76 0.591 –
Malignant tumor, n 7 91 0.436 – 15 83 0.711 –
PPCs, postoperative pulmonary complications; BMI, body mass index; CCI, Charlson Comorbidity index; CEA, carcinoembryonic antigen; 
KL-6, sialylated carbohydrate antigen; FeNO, fractional exhaled nitric oxide; BNP, brain natriuretic peptide; VC, vital capacity; FEV1.0, 
forced expiratory volume in 1 s.
clinically implement perioperative management based on 
FeNO.
This was the first prospective study to evaluate and 
analyze perioperative airway epithelial inflammation and 
surgical outcomes in patients who underwent lung resection 
in a quantitative manner. The basic objective of this study 
was to explore patients at an increased risk and to investigate 
the feasibility of perioperative management strategies using 
FeNO. This was a single-center clinical study. Thus, there 
may have been selection, measurement, and follow-up bias. 
Moreover, cases involving severe invasive surgery, such 
as bronchoplasty and pneumonectomy were not included 
in this study; therefore, other risk factors may require 
complete consideration in patients requiring extended 
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Figure 2 Comparison of FeNO levels before and after surgery. Box plot showing the distribution of preoperative and postoperative (peak) 
FeNO levels. These levels were compared for each patient and for each surgical procedure. Box plot key: upper horizontal line of the box, 
75th percentile; lower horizontal line of the box, 25th percentile; horizontal bar within the box, median; upper horizontal bar outside the box, 
90th percentile; lower horizontal bar outside the box, 10th percentile Circles represent outliers. Pre-FeNO, preoperative fractional exhaled 
































Figure 3 Transition of postoperative FeNO levels and modified CAT score for each surgical procedure. Box plot showing the distribution 
of values on the first, third, and fifth to seventh day, postoperatively. (A,D) correspond to patients who underwent lobectomy; (B,E) 
correspond to patients who underwent segmentectomy; and (C,F) correspond to patients who underwent wedge resection. Box plot key: 
upper horizontal line of the box, 75th percentile; lower horizontal line of the box, 25th percentile; horizontal bar within the box, median; 
upper horizontal bar outside the box, 90th percentile; lower horizontal bar outside the box, 10th percentile Circles represent outliers. FeNO, 
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Table 3 Variables and analysis data of the predictors according to respiratory-event related additional treatment
Variables











Male, n 23 34 0.802 – 2 55 0.329 –
Age (years) 67.6±11.9 68.8±8.6 0.587 – 75.0±0.0 68.1±10.1 0.343 –
BMI ≥25 (kg/m2), n 10 10 0.383 – 0 20 0.635 –
Smoking, Brinkman index 448±555 570±601 0.308 – 1225±176 505±579 0.084 0.066
Performance status 1, n 1 2 0.774 – 0 3 0.950 –
CCI score 1.3±1.3 1.0±1.4 0.185 0.277 2.0±0.0 1.1±1.4 0.279 0.350
Tumor diameter (mm) 14.1±8.8 19.2±15.5 0.041 0.050 18.0±0.0 17.1±13.4 0.927 –
CEA (ng/mL) 3.8±2.5 4.8±3.5 0.110 0.309 5.8±4.3 4.4±3.2 0.554 –
KL-6 (U/mL) 318±199 282±130 0.322 498±26.9 293±162 0.077 0.076
Preoperative FeNO (ppb) 31.6±23.4 23.4±11.8 0.044 0.750 24.5±12.0 26.9±18.1 0.854 –
Postoperative FeNO (ppb) 42.4±28.3 26.0±11.5 0.001 0.001 37.0±8.5 32.7±21.9 0.784 –
BNP (pg/mL) 23.5±22.9 32.6±46.5 0.252 – 48.2±13.9 28.4±38.9 0.477 –
Hemoglobin A1c, (%) 5.9±0.6 5.9±0.6 0.697 – 6.2±0.2 5.9±0.6 0.562 –
VC (mL) 3,318±886 3,328±751 0.953 – 3,455±247 3,320±813 0.817 –
%VC (%) 103±15.3 102±13.0 0.875 – 97.3±7.5 103±14.1 0.567 –
FEV1.0 (mL) 2,390±716 2,419±621 0.831 – 2,470±156 2,406±665 0.892 –
%FEV1.0 (%) 95.8±19.3 96.7±15.1 0.807 – 89.6±5.2 96.5±17.0 0.571 –
Operative time (min) 239±92 243±99 0.879 – 176±99.7 243±95.3 0.332 –
Operative blood loss (mL) 50.7±68.7 72.1±107 0.263 – 45.0±42.4 63.6±94.3 0.782 –
Lobectomy, n 25 42 0.231 0.643 1 66 0.544 –
Anatomical lung resection, n 33 48 0.773 0.676 1 80 0.332 –
Open thoracotomy, n 3 10 0.150 – 0 13 0.753 –
Lung cancer, n 36 50 0.817 – 2 84 0.753 –
Malignant tumor, n 39 54 0.514 – 2 91 0.882 –
PPCs, postoperative pulmonary complications; BMI, body mass index; CCI, Charlson Comorbidity index; CEA, carcinoembryonic antigen; 
KL-6, sialylated carbohydrate antigen; FeNO, fractional exhaled nitric oxide; BNP, brain natriuretic peptide; VC, vital capacity; FEV1.0, 
forced expiratory volume in 1 s.
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surgery.
In  summary,  our  ana l y s i s  demons t r a t ed  tha t 
perioperative FeNO was a significant predictor of surgical 
outcome among patients who underwent lung resection. 
Measurement of FeNO is a simple and useful method for 
preventing subsequent deterioration status in such patients.
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